Search research articles
Contact Us
Filters
Showing results (301-310 of 636) with videos related to
Page
of 64
Sort By:
Hepatology (Baltimore, Md.)
|
June 15, 2007
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman, Apurva Modi, David E Kleiner, et al.
Alimentary Pharmacology & Therapeutics
|
April 6, 2026
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies
Naim Alkhouri, Naga Chalasani, Zobair Younossi, et al.
JHEP Reports : Innovation in Hepatology
|
April 24, 2026
The future of hepatology: Preventing liver disease together with the public, scientists and artificial intelligence
Benjamin P M Laevens, Corinna Meeßen, Frank P Pijpers, et al.
The Lancet. Gastroenterology & Hepatology
|
June 8, 2025
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
Rohit Loomba, Kris V Kowdley, Jose Rodriguez, et al.
Nuclear Medicine and Biology
|
February 14, 2016
Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models
Bernd Schnabl, Salman Farshchi-Heydari, Rohit Loomba, et al.
Alimentary Pharmacology & Therapeutics
|
March 25, 2021
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease
Jung Gil Park, Jinho Jung, Kritin K Verma, et al.
Hepatology International
|
April 17, 2023
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease
Min Kyu Kang, Yu Rim Lee, Se Young Jang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 10, 2015
Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis
Ahilan Arulanandan, Brandon Ang, Ricki Bettencourt, et al.
Contemporary Clinical Trials
|
July 2, 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
Vlad Ratziu, Arun J Sanyal, Rohit Loomba, et al.
Microbiome
|
January 14, 2025
Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease
Emmanouil Nychas, Andrea Marfil-Sánchez, Xiuqiang Chen, et al.
Page
of 64
Search research articles
Search
Showing results (301-310 of 636) with videos related to
Sort By:
Page
of 64
Hepatology (Baltimore, Md.)
|
June 15, 2007
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman, Apurva Modi, David E Kleiner, et al.
Alimentary Pharmacology & Therapeutics
|
April 6, 2026
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies
Naim Alkhouri, Naga Chalasani, Zobair Younossi, et al.
JHEP Reports : Innovation in Hepatology
|
April 24, 2026
The future of hepatology: Preventing liver disease together with the public, scientists and artificial intelligence
Benjamin P M Laevens, Corinna Meeßen, Frank P Pijpers, et al.
The Lancet. Gastroenterology & Hepatology
|
June 8, 2025
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
Rohit Loomba, Kris V Kowdley, Jose Rodriguez, et al.
Nuclear Medicine and Biology
|
February 14, 2016
Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models
Bernd Schnabl, Salman Farshchi-Heydari, Rohit Loomba, et al.
Alimentary Pharmacology & Therapeutics
|
March 25, 2021
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease
Jung Gil Park, Jinho Jung, Kritin K Verma, et al.
Hepatology International
|
April 17, 2023
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease
Min Kyu Kang, Yu Rim Lee, Se Young Jang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 10, 2015
Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis
Ahilan Arulanandan, Brandon Ang, Ricki Bettencourt, et al.
Contemporary Clinical Trials
|
July 2, 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
Vlad Ratziu, Arun J Sanyal, Rohit Loomba, et al.
Microbiome
|
January 14, 2025
Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease
Emmanouil Nychas, Andrea Marfil-Sánchez, Xiuqiang Chen, et al.
Page
of 64